Plain-English translation of NCT06449885 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a long-term observational study that follows people who have been newly diagnosed with marginal zone lymphoma, a type of blood cancer. Researchers will collect information about your diagnosis, the type of treatment you receive, and how you respond over time. The goal is to build a clearer picture of how different subtypes of this disease progress and which treatments are most effective.
Marginal zone lymphoma is a complex disease with several different subtypes, and doctors don't yet have clear guidelines about which treatment approach works best for each patient. This study exists to gather real-world information about how the disease develops, what treatments patients receive, and what outcomes they experience — knowledge that will help doctors make better treatment decisions in the future.
You likely qualify if…
You likely don't qualify if…
You would visit the hospital regularly for appointments where researchers will collect information about your health, your diagnosis, and any treatment you receive from your doctor. You'll provide blood samples and allow access to your tumor tissue samples for study purposes. Over months and years, the research team will track how your condition progresses and how you respond to whatever treatment your doctor recommends, building a detailed picture of your disease course.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China
Sponsor
Fudan University
Enrollment target
~2,500 participants
Started
May 2024
Primary completion
June 2029
Age range
18 Years and older
Last updated on clinicaltrials.gov in November 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Rong Tao, M.D
Fudan University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.